Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients
Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients
复制标题
DOI：
10.1097/00007890-199712270-00036
复制
发表时间：
1997-12-27
期刊：
影响因子：
6.2
通讯作者：
Storch, GA
中科院分区：
文献类型：
--
作者：
Brennan, DC;Garlock, KA;Storch, GA
背景。肾移植患者预防性口服阿昔洛韦、静脉注射更昔洛韦或免疫球蛋白预防巨细胞病毒（CMV）感染和疾病的治疗效果不一，费用也很大。我们研究了肾移植受者CMV的控制，采用预防性口服更昔洛韦或延迟治疗，并采用聚合酶链反应（PCR）分析进行强化监测。42例移植后随访6个月。移植时开始使用更昔洛韦（每日1000 mg，每日1次；n=19）或阿昔洛韦（每日200 mg，每日1次；n=23）并持续12周。在第15周和第5、6个月，每周对绒毛标本进行CMV PCR检测。更昔洛韦组无患者，而延期治疗组23例患者中有14例（61%）(P
Background. Treatment with prophylactic oral acyclovir, intravenous ganciclovir, or immunoglobulins to prevent cytomegalovirus (CMV) infection and disease in renal transplantation is associated with variable efficacy and significant expense. We studied control of CMV in renal transplant recipients using either prophylactic oral ganciclovir or deferred therapy with intensive monitoring with polymerase chain reaction (PCR) analysis.Methods. Forty-two recipients were followed for 6 months after transplantation. Ganciclovir (1000 mg p.o. t.i.d.; n=19) or acyclovir (200 mg p.o. b.i.d.; n=23) was begun at transplantation and continued for 12 weeks. PCR for CMV was performed on huffy-coat specimens every week for 15 weeks and at months 5 and 6.Results. No patients in the ganciclovir group, compared with 14 of 23 patients (61%) in the deferred-therapy group (P